---
title: "Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, R... — FDA record D-0727-2022 | Is It on Recall"
description: "Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample"
url: https://isitonrecall.com/recall/fda-drug-d-0727-2022-clotrimazole-and-betamethasone-dipropionate-cream-usp-1-0-05-15-g-tubes-rx-only-manufactured-by-taro/
updated: 2026-10-01
site: "Is It on Recall"
language: en
---

[Recall archive](https://isitonrecall.com/archives/) / FDA drug enforcement

# Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceut... — FDA record D-0727-2022

Reported terminated

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Feb 25, 2022. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; [check FSIS directly](https://www.fsis.usda.gov/recalls). [Source coverage and dates](https://isitonrecall.com/sources/).

## What the record says

- **Product**: Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4048-1
- **Reason**: Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample
- **Classification**: Class III
- **Recalling firm**: Taro Pharmaceuticals U.S.A., Inc.
- **Quantity**: 768 tubes
- **Agency-reported status**: Terminated
- **Source record identifier**: D-0727-2022

[Open the official record](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0727-2022%22)

[What the recall classes mean](https://isitonrecall.com/guides/recall-classes/). Classification is an agency assessment, not individual medical advice.

## Lot and product identifiers

| Label field | Details supplied by the agency |
| --- | --- |
| Lot, code or applicability | Lot #: AC33883, Exp. Date June 2023 |

Match all identifying details in the current notice. A brand name alone is not enough.

## Distribution

Product was distributed to one retail consignee in NY.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

- [New York](https://isitonrecall.com/state/new-york/)

## Dates in the source

- **Report date**: Apr 6, 2022
- **Recall initiation date**: Feb 25, 2022
- **Center classification date**: Mar 29, 2022
- **Termination date**: Sep 9, 2024

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

## What to do next

Read the official notice for the action that applies to your exact product.

[Read the current instructions](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0727-2022%22)

## Before changing a medicine

Follow urgent instructions in the current official recall notice. Speak to your pharmacist or prescriber before stopping or changing a prescribed medicine.

Talk to your doctor or pharmacist if you have questions or concerns about your medicine. [FDA medication recall guidance](https://www.fda.gov/drugs/drug-recalls/understanding-drug-recalls-what-know-and-what-do)

## Related records

[Medications records](https://isitonrecall.com/category/medications/) [Taro Pharmaceuticals U.S.A., Inc. records](https://isitonrecall.com/brand/taro-pharmaceuticals-u-s-a-inc/)